<--- Back to Details
| First Page | Document Content | |
|---|---|---|
 Date: 2011-10-12 15:20:19Darunavir Etravirine Lopinavir/ritonavir Ritonavir Atazanavir Antiretroviral drug Lopinavir Tipranavir Tibotec Chemistry Organic chemistry Protease inhibitors |
 | HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use FULYZAQ safely and effectively. See full prescribing information for FULYZAQ. FULYZAQ ® (crofelemer) delayed-releasDocID: 1gtlL - View Document |
 | SUPPLEMENT ARTICLE Drug-Drug Interactions in the Treatment of HCV Among People Who Inject Drugs Stefan Mauss1 and Hartwig Klinker2 1DocID: 1giaR - View Document |
 | AIDS Research and Therapy BioMed Central ResearchDocID: 1aNo3 - View Document |
 | MS&D logo_no qualifier_2 linesDocID: 1a8lZ - View Document |
 | Data from the FLAMINGO Phase IIIb/IV Study of the Integrase Inhibitor Tivicay® (dolutegravir), Disclosed by ViiV Healthcare Osaka, Japan, September 13, Shionogi & Co., Ltd. (Head Office: Osaka; President & CEO: IDocID: 1a178 - View Document |